-
Mashup Score: 0Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets - 14 day(s) ago
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Tune in to watch a panel lead by @dradityabardia discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing. https://t.co/he4iLL2d5H
-
-
Mashup Score: 1
Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Patient Guidance and Care Drives McCann’s Passion as a Woman in Oncology @DrKEMcCann @UCLAHealth #WomenInOncology #BCSM https://t.co/e2qqAOdV7e
-
-
Mashup Score: 1Comprehensive Communication Regarding CRC Surgery and Postoperative Complications Is Crucial - 14 day(s) ago
Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Read more here: https://t.co/53V1mxjUXV
-
-
Mashup Score: 3
PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
PEP-010 Wins FDA Orphan Drug Designation in Metastatic Pancreatic Cancer #pancsm @US_FDA #PancreaticCancer https://t.co/8IikGI3prL
-
-
Mashup Score: 5
Reshma Jagsi, MD, DPhil, highlights her journey to becoming a radiation oncologist and the nuances of intersectionality as a woman in oncology.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Intersectionality, Leadership, and Empowerment Drive Jagsi as a Woman in Oncology @reshmajagsi @WinshipatEmory #WomenInOncology #BCSM https://t.co/HDYnvhNX2s
-
-
Mashup Score: 2FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL - 15 day(s) ago
The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL @US_FDA #lymsm #hematology https://t.co/4Yk7xn001h
-
-
Mashup Score: 2IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL - 15 day(s) ago
Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL #lymsm #oncology #MedEd https://t.co/Y03r6meQrX
-
-
Mashup Score: 4PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC - 15 day(s) ago
Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC @MoffittNews #pcsm https://t.co/q587e3EPnU
-
-
Mashup Score: 0
The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has granted fast track designation to the novel, first-in-class, oral KAT2A/B degrader AUTX-703 for the treatment of patients with relapsed/refractory #AML. #leusm #FDA https://t.co/L5Lydhe0e8 https://t.co/xGKTjnxLJv
-
Hear Timothy Pluard, MD and Ruta Rao, MD discuss how trastuzumab deruxtecan is used to treat HER2-positive metastatic breast cancer with brain metastases. Watch more here: https://t.co/td46hswtbt